Further studies in an orthotopic Hepa1-6 hepatoma mouse model using a micro-osmotic pump for targeted PERK inhibitor delivery demonstrated that the delivery of the inhibitor to the spleen rather than the tumor was most effective at limiting cancer associated myelopoiesis, and resulted in enhanced tumor infiltration by IFNγ+ CD8 T cells and delayed disease progression (51). The gene discussed is CD8A; the disease is hepatocellular carcinoma.